Jun 14, 2022 / 08:20PM GMT
Chris Cooper - Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay. Good afternoon, everyone. For the next session, we are fortunate to be joined by Mick Farrell, the CEO of ResMed. Most of you will know they are a leading player in sleep and respiratory health globally. Thanks for joining us, Mick.
Michael J. Farrell - ResMed Inc. - CEO & Director
Happy to be here. Thanks for having me.
Questions and Answers:
Chris Cooper - Goldman Sachs Group, Inc., Research Division - Research AnalystLet's get straight into it. So overnight, you announced a $1 billion acquisition. Unfortunately, many of us here would have missed the call that you hosted this morning. Perhaps you could just run us through the final points and contextualize the German business for us and walk us through the value proposition.
Michael J. Farrell - ResMed Inc. - CEO & Director
Yes, absolutely. And we didn't intend M&A goes at the speed it goes. We didn't intend to -- for